SCHEMBL4159786

SCHEMBL4159786

ON=Cc1ccn(C2CCCc3c2[nH]c2ccc(Br)cc32)c1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.65
CYP2D6 P10635 3/20 0.44
KCNH2 Q12809 1/20 0.41
MAPT P10636 4/20 0.39
LMNA P02545 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
SIRT1 Q96EB6 9/20 0.38
ALDH1A1 P00352 2/20 0.37
MAPK1 P28482 1/20 0.37
HTR2A P28223 2/20 0.35
HTR2C P28335 2/20 0.35
SIRT2 Q8IXJ6 3/20 0.35
SIRT3 Q9NTG7 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4159785 1.00 DHODH (0.65) DHODHCYP2D6KCNH2MAPTLMNA
SCHEMBL16433423 0.87 DHODH (0.61) DHODHCYP2D6KCNH2MAPTLMNA
SCHEMBL4161198 0.87 DHODH (0.69) DHODHCYP2D6KCNH2MAPTLMNA
SCHEMBL4163871 0.80 DHODH (0.67) DHODHCYP2D6KCNH2MAPTLMNA
SCHEMBL4152072 0.79 DHODH (1.00) DHODHCYP2D6KCNH2MAPTLMNA
SCHEMBL4165397 0.78 DHODH (0.69) DHODHCYP2D6KCNH2MAPTLMNA
SCHEMBL16433416 0.78 DHODH (0.69) DHODHCYP2D6KCNH2MAPTLMNA
SCHEMBL16433485 0.78 DHODH (0.65) DHODHCYP2D6KCNH2MAPTLMNA
SCHEMBL16433419 0.77 DHODH (0.64) DHODHCYP2D6KCNH2MAPTLMNA
SCHEMBL4150733 0.77 DHODH (0.62) DHODHCYP2D6KCNH2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control VEGFA, FLT4, KDR DHODH 668/4885CYP2D6 4677/4885KCNH2 4634/4885
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL VEGFA, FLT4, KDR DHODH 668/4885CYP2D6 4677/4885KCNH2 4634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.